- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04971161
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)
A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, placebo-controlled, double-blind, dose-ranging, multicenter, phase IIb clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-CVU on wound healing in patients with therapy-resistant CVU. The allogeneic IMP allo-APZ2-CVU contains skin-derived ABCB5-positive dermal mesenchymal stromal cells isolated from skin tissue of healthy donors and stored in a donor cell bank.
Patients will be randomized to be treated with allo-APZ2-CVU (dose 1, dose 2, dose 3) or placebo (50 patients per dose group). The patients will undergo treatment with the IMP on Day 0 (V3) and will be followed up for efficacy for 18 weeks (V4 until V14). Two safety follow-up visits will be performed at Month 6 (V15) and Month 10 (V16).
The wound healing process will be documented by standardized photography. The wound size measurement will start at the first Screening Visit (V1) and will be measured at each following on-site visit.
Pain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Christoph Ganss, Dr.
- Phone Number: +49 6221 71833
- Email: office@rheacell.com
Study Contact Backup
- Name: Anna Mößmer
- Phone Number: +49 6221 71833
- Email: anna.moessmer@rheacell.com
Study Locations
-
-
-
Aachen, Germany, 52066
- Recruiting
- MVZ Gefäßzentrum Aachen am Marienhospital Aachen GmbH
-
Contact:
- Jens D Puschmann
-
Augsburg, Germany, 86179
- Recruiting
- Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd
-
Contact:
- Julia Welzel, Prof. Dr.
-
Bad Bentheim, Germany, 48455
- Recruiting
- Fachklinik Bad Bentheim, Dermatologische Ambulanz
-
Contact:
- Athanasios Tsianakas, PD Dr. med.
-
Berlin, Germany, 13125
- Recruiting
- Helios Klinikum Berlin-Buch, Klinik für Plastische und Ästhetische Chirurgie
-
Contact:
- Oliver C. Thamm, PD Dr. med.
-
Berlin, Germany, 14165
- Recruiting
- Helios Klinikum Emil von Behring, Klinik für Plastische und Ästhetische Chirurgie
-
Contact:
- Daniel Schiltz, Dr. med.
-
Berlin, Germany, 10787
- Withdrawn
- Franziskus-Krankenhaus Berlin, Klinik für Innere Medizin, Angiologie und Diabetologie
-
Bochum, Germany, 44793
- Recruiting
- Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Hautzentrum im Jahrhunderthaus
-
Contact:
- Johannes Niesmann, Dr. med.
-
Bochum, Germany, 44805
- Recruiting
- Katholisches Klinikum Bochum gGmbH, Venenzentrum der Kliniken für Dermatologie und Gefäßchirurgie der Ruhr-Universität Bochum
-
Contact:
- Markus Stücker, Prof. Dr.
-
Braunschweig, Germany, 38100
- Recruiting
- Hautärzte Braunschweig am Altstadtmarkt, Hautärztliche Gemeinschaftspraxis
-
Contact:
- Herms Wittstock, Dr. med.
-
Bremerhaven, Germany, 27574
- Recruiting
- Klinikum Bremerhaven Reinkenheide gGmbH, Klinik für Dermatologie, Allergologie und Phlebologie, Wundzentrum
-
Contact:
- Michael M. Sachse, Dr. med.
-
Dresden, Germany, 01069
- Recruiting
- Klinische Forschung Dresden GmbH
-
Contact:
- Peter Heymer, Dr. med.
-
Dresden, Germany, 01307
- Withdrawn
- Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden, Medizinische Klinik und Poliklinik III Angiologie und Gefäßzentrum
-
Düsseldorf, Germany, 40225
- Withdrawn
- Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Klinik für Dermatologie
-
Erlangen, Germany, 91054
- Recruiting
- Universitätsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie
-
Contact:
- Cornelia Erfurt-Berge, PD Dr. med.
-
Essen, Germany, 45147
- Recruiting
- Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
-
Contact:
- Joachim Dissemond, Prof. Dr.
-
Freiburg, Germany, 79104
- Terminated
- Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie
-
Gelsenkirchen, Germany, 45886
- Recruiting
- Marienhospital Gelsenkirchen GmbH, Klinik für Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gefäß- und Endovaskuläre Chirurgie und Kinderchirurgie)
-
Contact:
- Mansur Duran, PD Dr. med.
-
Gera, Germany, 07548
- Recruiting
- SRH Wald-Klinikum Gera GmbH, Zentrum für Klinische Studien
-
Contact:
- Sabine Sell
-
Greifswald, Germany, 17475
- Recruiting
- Universitätsmedizin Greifswald, Klinik und Poliklinik für Hautkrankheiten
-
Contact:
- Stine Lutze, Dr. med.
-
Halle, Germany, 06108
- Recruiting
- Praxis Dr. med. Abdou Zarzour
-
Contact:
- Abdou Zarzour, Dr. med.
-
Hamburg, Germany, 20246
- Recruiting
- Universitätsklinikum Hamburg- Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP)
-
Contact:
- Matthias Augustin, Prof. Dr.
-
Hanau, Germany, 63450
- Recruiting
- MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH
-
Contact:
- Hans Michael Ockenfels, Prof. Dr.
-
Hannover, Germany, 30459
- Recruiting
- Klinikum Region Hannover GmbH, KRH Klinikum Siloah, Klinik für Nephrologie, Angiologie und Rheumatologie
-
Contact:
- Jan Menne, Prof. Dr.
-
Heidelberg, Germany, 69115
- Recruiting
- Zentrum für Dermatochirurgie, St. Josefskrankenhaus Heidelberg GmbH
-
Contact:
- Moritz Felcht, Prof. Dr.
-
Karlsbad, Germany, 76307
- Recruiting
- SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplinäres Gefäßzentrum Innere Medizin
-
Contact:
- Rüdiger von Bauer, Dr. med.
-
Kiel, Germany, 24148
- Terminated
- Medizinisches Versorgungszentrum DermaKiel GmbH
-
Krefeld, Germany, 47805
- Withdrawn
- Helios Klinikum Krefeld, Klinik für Dermatologie und Venerologie
-
Langenau, Germany, 89129
- Recruiting
- Hautarztpraxis Langenau, Studienzentrum
-
Contact:
- Beate Schwarz, Dr. med.
-
Leipzig, Germany, 04103
- Recruiting
- Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
-
Contact:
- Jan C. Simon, Prof. Dr.
-
Leipzig, Germany, 04315
- Withdrawn
- Studienambulanz Dr. Schubert Leipzig
-
Ludwigshafen, Germany, 67059
- Recruiting
- Diabetologikum Ludwigshafen, die Praxis am Ludwigsplatz
-
Contact:
- Lutz Stemler, Dr. med.
-
Memmingen, Germany, 87700
- Recruiting
- Beldio Research GmbH
-
Contact:
- Andreas Schwinn, Dr. med.
-
München, Germany, 80337
- Recruiting
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie
-
Contact:
- Daniela Hartmann, PD Dr. med.
-
München, Germany, 80636
- Withdrawn
- Dermazentrum München, Standort Neuhausen, Studienzentrum
-
Münster, Germany, 48149
- Recruiting
- Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie
-
Contact:
- Tobias Görge, Prof. Dr.
-
Nürnberg, Germany, 90419
- Recruiting
- Klinikum Nürnberg Nord, Klinik für Dermatologie
-
Contact:
- Erwin S. Schultz, Prof. Dr.
-
Potsdam, Germany, 14467
- Recruiting
- MVZ Corius Potsdam GmbH, Dermatologie Potsdam MVZ
-
Contact:
- Khusru Asadullah, Prof. Dr.
-
Regensburg, Germany, 93053
- Recruiting
- Caritas-Krankenhaus St. Josef, Klinik für Plastische und Ästhetische, Hand- und Wiederherstellungschirurgie
-
Contact:
- Stephan Seitz, PD Dr. med.
-
Rostock, Germany, 18057
- Recruiting
- Universitätsmedizin Rostock, Klinik und Poliklinik für Dermatologie und Venerologie
-
Contact:
- Susen Rode
-
Schwerin, Germany, 19049
- Recruiting
- Helios Kliniken Schwerin, Plastische, Rekonstruktive und Ästhetische Chirurgie
-
Contact:
- Frank Masberg, Dr. med.
-
Stuttgart, Germany, 70178
- Recruiting
- Hautärztliche Gemeinschaftspraxis Dr. Leitz und Kollegen
-
Contact:
- Nicolas Leitz, Dr. med.
-
Tübingen, Germany, 72076
- Recruiting
- Universitätsklinikum Tübingen, Universitäts-Hautklinik Tübingen
-
Contact:
- Anke Strölin, Prof. Dr.
-
Wuppertal, Germany, 42283
- Recruiting
- Helios Universitätsklinikum Wuppertal, Zentrums für Dermatologie, Allergologie und Dermatochirurgie
-
Contact:
- Silke C. Hofmann, Prof. Dr.
-
Würzburg, Germany, 97080
- Recruiting
- Universitätsklinikum Würzburg, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
-
Contact:
- Andreas Kerstan, PD Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients at least 18 years old;
- Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy-resistant ulcer that shows no tendency to heal within 3 months despite of optimal phlebological therapies or has not fully healed within 12 months) at lower leg and/or ankle region and has not been present longer than 15 years, diagnosed by doppler or duplex sonography, ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological review;
- Wound size of target ulcer between 1 and 50 cm² measured by a standardized photography at the screening visit;
- If patients have 2 or more ulcers at the same extremity, the target ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise at discretion of the investigator; the target ulcer is defined at Visit 1);
- Body mass index between 15 and 50 kg/m²;
- Patients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;
- Women of childbearing potential must have a negative blood pregnancy test at Visit 1;
- Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.
Exclusion Criteria:
- Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
- Diabetes mellitus that has to be confirmed by blood test (Hemoglobin A1c >7.5%);
- Peripheral Artery Disease including claudication with need of treatment;
- Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;
- Unable to tolerate leg ulcer compression bandage;
- Infection of the target ulcer requiring treatment as judged clinically;
- All diagnosed disorders, unrelated to CVU, that are influencing wound healing of the target wound at investigator's discretion;
- Current use of medications that influence wound healing: systemic immunosuppressives, cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);
- Patient who, in the opinion of the investigator, for any reason are unable or unwilling to complete the trial per protocol (e.g. alcohol or substance abuse, not mobile, short life expectancy) or there is evidence of any other medical condition (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
- Any malignancy within the past 5 years, excluding successfully treated carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin without evidence of metastases;
- Pregnant or lactating women;
- Any known allergies to components of the IMP;
- Prior surgical procedures such as bypass or mesh-graft treatment at target leg within 2 months prior to Visit 1 at target leg;
- Patients with significant ulcer healing or wound size enlargement of more than 25% at Visit 2 compared to Visit 1;
- Treatment of target ulcer with active wound care agents (e.g. Iruxol®N), which have not been paused 14 days before IMP application;
- Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
- Previous participation in this clinical trial (except for screening failures due to an inclusion or exclusion criterion);
- Employees of the sponsor, or employees or relatives of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)
Application of IMP on patients wound
|
Suspension of ABCB5-positive dermal mesenchymal stromal cells.
One topical application with a syringe.
Other Names:
|
Placebo Comparator: Placebo
Application of IMP on patients wound
|
One topical application with a syringe
|
Experimental: allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)
Application of IMP on patients wound
|
Suspension of ABCB5-positive dermal mesenchymal stromal cells.
One topical application with a syringe.
Other Names:
|
Experimental: allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)
Application of IMP on patients wound
|
Suspension of ABCB5-positive dermal mesenchymal stromal cells.
One topical application with a syringe.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete wound closure at Week 18 already persisting for at least two weeks
Time Frame: Week 18
|
Complete wound closure at Week 18 already persisting for at least two weeks will be evaluated.
|
Week 18
|
Assessment of adverse event (AE) occurrence
Time Frame: Up to 10 months
|
All AEs occurring during the clinical trial will be registered, documented and evaluated.
|
Up to 10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound size change in percent at each post-baseline follow-up visit
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Wound size change in percent at each post-baseline follow-up visit will be evaluated.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Time to complete wound closure
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Time to complete wound closure will be evaluated.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Complete wound closures at each post-baseline follow-up visit
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Complete wound closures at each post-baseline follow-up visit will be evaluated.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Duration of wound closure
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Duration of wound closure will be evaluated.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Recurrence of the wound
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Recurrence of the wound will be evaluated.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Quality of wound healing (wound exudate) at each post-baseline follow-up visit
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the amount and type of wound exudate.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the formation of granulation tissue together with epithelialization.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Quality of wound healing (scar formation) at each post-baseline follow-up visit
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the questions regarding scar formation.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14
Time Frame: Week 6, 12, 18
|
Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14 will be evaluated.
|
Week 6, 12, 18
|
Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit
Time Frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit will be evaluated.
|
Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10
|
Physical examination and vital signs at V14
Time Frame: Week 18
|
A physical body examination (e.g.
general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs.
|
Week 18
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andreas Kerstan, Dr., Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- allo-APZ2-CVU-IIb
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Ulcer Venous Stasis Chronic
-
Inotec AMD LimitedWithdrawnSkin Ulcer Venous Stasis Chronic | Mixed Arteriovenous Leg UlcerCzechia
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesCompleted
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesTerminatedSkin Ulcer Venous Stasis ChronicGermany
-
ACR Biologics, LLCTerminatedPressure Ulcer | Skin Ulcer Venous Stasis Chronic | Foot Ulcer ChronicUnited States
-
PolarityTEProfessional Education and Research InstituteCompletedVenous Leg Ulcer | Venous Stasis | Venous Stasis UlcerUnited States
-
Erchonia CorporationTerminatedVenous Stasis UlcerUnited States, France
-
West Penn Allegheny Health SystemThe Cleveland Clinic; Tactile Systems Technology, Inc.Terminated
-
HealthpointTerminatedUlcer | Venous Ulcer | Venous Stasis UlcerGermany, Poland, Belgium, Czech Republic, Hungary
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Merakris TherapeuticsUS Department of Veterans AffairsRecruitingVenous Leg Ulcer | Venous Stasis UlcerUnited States
Clinical Trials on allo-APZ2-CVU
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesCompleted
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesCompletedDiabetic Neuropathic UlcerGermany
-
RHEACELL GmbH & Co. KGRecruiting
-
RHEACELL GmbH & Co. KGRecruitingEpidermolysis BullosaUnited States
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesCompletedRecessive Dystrophic Epidermolysis BullosaUnited States, Austria, France, Germany, United Kingdom
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesTerminatedPeripheral Arterial Occlusive DiseaseGermany, Austria, Czechia, Poland, United Kingdom
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbHTerminatedAcute-On-Chronic Liver FailureGermany
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesTerminatedSkin Ulcer Venous Stasis ChronicGermany
-
Anterogen Co., Ltd.RecruitingCrohn's DiseaseKorea, Republic of
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting